Name of Journal: *World Journal of Meta-Analysis*

Manuscript NO: 47569

Manuscript Type: MINIREVIEWS

Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump

Naina Mohamed Pakkir Maideen

Abstract

Dipeptidyl peptidase 4 (DPP4) inhibitors are oral antidiabetic drugs approved to manage type 2 diabetes mellitus. Saxagliptin is a substrate of CYP3A4/5 enzymes while other DPP4 inhibitors such as Sitagliptin, Linagliptin, Gemigliptin and Teneligliptin are weak substrates of CYP3A4. DPP4 inhibitors have also been identified as the substrates of P-gp. Hence, the drugs inhibiting or inducing CYP3A4/5 enzymes and/or P-gp can alter the pharmacokinetics of DPP4 inhibitors. This review is aimed to identify the drugs

国内版 国际版

Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and I

All Images Videos 翻译成中文 关闭取词

4,530 Results Any time

Drug interactions of meglitinide antidiabetics involving ...

https://www.researchgate.net/publication/324261559_**Drug**...

This article focuses on the **drug interactions** of meglitinides **involving CYP enzymes** and OATP1B1 transporter. ... (**P-gp**) and **cytochrome P450** (**CYP**) 3A4 activity was evaluated. ... glucacon-like ...

Drug interactions with oral antidiabetic agents ...

https://www.sciencedirect.com/science/article/pii/S0165614712000338

With the exception of saxagliptin, a substrate of CYP3A4, DPP-**4 inhibitors** seem to be devoid of strong DDIs **involving CYP enzymes**. However, some evidence already exists that inhibition or induction of **drug** transporters (e.g. **P-gp**) can affect the pharmacokinetics of different DPP-**4 inhibitors**. More research in this area is needed.

Cited by: 84 **Author:** Aleksi Tornio, Mikko Niemi, Pertti J. Neuv…
Publish Year: 2012

Clinical pharmacology of dipeptidyl peptidase 4 inhibitors ...

onlinelibrary.wiley.com/doi/10.1111/1440-1681.12455/full

Dipeptidyl peptidase-4 inhibitors reduce plasma DPP-**4** activity by 70–90% in a sustained manner for 24 h with an increase of GLP-1 levels (1.5- to **4**-fold). They do not pass the blood–brain barrier, have no direct central effect on satiety, and in contrast with GLP-1 …

Published in: Clinical and Experimental Pharmacology and Physiology · 2015
Authors: Xiao Wu Chen · Zhi Xu He · Zhiwei Zhou · Tianxin Yang · Xueji Zhang · Yin Xue Yang
Affiliation: Southern Medical University · Guiyang Medical University · University of South Florida
About: Type 2 diabetes · Teneligliptin · Glucagon-like peptide-1 · Beta-cell Function · **Dipepti**…